Clinical trial
A Phase 2b/3 Study to Evaluate the Safety, Tolerability, and Effects of Livoletide (AZP-531), an Unacylated Ghrelin Analogue, on Food-related Behaviors in Patients With Prader-Willi Syndrome
NCT03790865 is registered in ClinicalTrials.gov with Millendo Therapeutics SAS as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b/3 Study to Evaluate the Safety, Tolerability, and Effects of Livoletide (AZP-531), an Unacylated Ghrelin Analogue, on Food-related Behaviors in Patients With Prader-Willi Syndrome
- Lead sponsor
- Millendo Therapeutics SAS
- Phase
- Phase 2/3
- Overall status
- Terminated
- Start date
- March 25, 2019
- Completion date
- May 25, 2020
- Enrollment
- 158 (actual)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.